EHDN has posted a revised ACR16 update of the European ACR16 trial:

[www.euro-hd.net]

What do you all think about this?

I followed the link, and clicked on the first PDF "revised...May 2010...."

It SOUNDS like the author of the report is hopeful that the revised data will NOT affect the speed of approval, and was clear to write the report stating many times that it is still clear that the drug works and seems safe.

But that the first dialog with approval agencies is scheduled but has yet to occur. So I guess I'll feel better once that happens.

And also hopeful that the North American study produces results that are statistically-significant enough to allow approval to proceed here too. (Plus maybe news of the N-Am study can slightly strengthen the case for approval in Europe too).

[www.hdsa.org]

Which I posted last week.

Sorry -- my mistake.

EHDN investigators to provide an independent review of the ACR-16 results:

[www.euro-hd.net]

Robi Blumenstein
CHDI Management/CHDI Foundation
robi.blumenstein@chdifoundation.org
www.chdifoundation.org

Thanks Robi, this is good news.